What's breaking now, across thousands of outlets.
Pfizer reports Phase 3 wins for Litfulo: The drug succeeded in two trials for active and stable nonsegmental vitiligo, an autoimmune condition that causes skin to progressively lose its color. One ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
More details have emerged about how the industry’s largest psychedelic biotech buyout came to fruition. In an SEC filing on Thursday morning, AtaiBeckley disclosed some of the play-by-play from its
Biopharma earnings season is also pipeline update season. On Thursday, Takeda, Regeneron, Sanofi and Bristol Myers Squibb all announced program cuts as part of their quarterly updates.
Dietary arginine reduces tumor formation and viral load in mice by boosting key immune proteins.
A new study finds that ocean temperatures thousands of kilometers away shape soil moisture in Malawi, offering a potential tool for forecasting malaria outbreaks months in advance.
Learn how to balance screen time and offline life, improve mental well-being, reduce digital stress, and build healthier daily habits. (And stay sane.)
The deal with the buzzy Flagship Pioneering-backed startup makes J&J the latest large drugmaker to bet that the technology might be able to treat autoimmune conditions.
